Company Description

Myogenica is developing MyoPAXon, an induced pluripotent stem cell (iPSC) platform for muscle regeneration. MyoPAXon has been shown to be effective in regenerating muscle and dramatically improving function in a range of muscular dystrophy models, including Duchenne muscular dystrophy, limb girdle muscular dystrophy and Facioscapulohumeral muscular dystrophy (FSHD).